Cornell Research Foundation Inc.

Sloan-kettering Institute for Cancer Research

Cornell University

Children's Medical Center Corporation

Imclone System Incorporated

Shahin Rafii

Fan Zhang

Marco Seandel

David C Lyden

Jay M Edelberg

Barbara L Hempstead

Sina Y Rabbany

Rosemary Kraemer

Phi Wiegn

Rosandra N Kaplan

Rebecca D Riba

Sergey V Shmelkov

Mun K Hong

Robert P Lanza

Michael D West

Mariana Lagos-Quintana

Malcolm A S Moore

Vivek Mittal

Michael J Donovan

Larry Witte

Linda Vahdat

Bi-Sen Ding

Rakhi Naik

Maureen Lane

Till Milde

Michael Ginsberg

Sai H Chavala

Jun Lin

Michael L Donovan

Brisa Palikuqi

Vladislav M Sandler

Daylon James

The present disclosure provides methods for forming stable three-dimensional vascular structures, such as blood vessels and uses thereof. More specifically, the present disclosure provides methods for culturing differentiated endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor on a matrix under conditions that express exogenous ETV2 protein in the endothelial cell to form stable three-dimensional artificial blood vessels without the use of a scaffold, pericytes or perfusion. The present disclosure also provides stable three-dimensional blood vessels that are capable of autonomously forming a functional three-dimensional vascular network, and uses thereof. In addition, the present disclosure includes methods for vascularizing an organoid and a decellularized organ by culturing the organoid or decellularized organ with endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor under conditions that express exogenous ETV2 protein in the endothelial cell to vascularize the organoid or decellularized organ.

Stable three-dimensional blood vessels and methods for forming the same

The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.

Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis

A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject.

Methods for organ regeneration

Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1hematopoietic progenitor cells (HPCs) and/or VEGFR2endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.

Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer

This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from amniotic cells. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.

Generation of functional and durable endothelial cells from human amniotic fluid-derived cells

The present invention relates to the microRNA miR-126 and to inhibitors of miR-126 that regulate angiogenesis. The present invention provides compositions and methods for the inhibition of miR-126 and for the inhibition of angiogenesis in vivo.

Inhibition of angiogenesis

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.

Methods for increasing vascular density and maintaining viability of microvascular endothelial cells using trk receptor ligands

The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene.

Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1bone marrow-derived cells to prior levels.

Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics

The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof.

Slitrks as markers for stem and progenitor cells and methods of use thereof

Methods for increasing capillary density and maintaining viability of microvascular cardiac endothelial cells using trk receptor ligands

The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.

Platelet-derived growth factor protection of cardiac myocardium

Growing community of inventors

Great Neck, NY, United States of America

Shahin Rafii